We create and deliver a unique technology for personalized,
non-invasive diagnostics

Our areas of interest are Life Science and Health care. We use innovative proprietary software to create fast, safe and accurate diagnostic tools to be available all over the world.

Mission & Vision

We provide our technology for personalized, harmless, and accurate diagnostics to reduce invasive procedures in healthcare.

We believe in innovative medicine that is transformed by AI technology from invasive procedures to patient-friendly, accurate, and safe methods in diagnostics and treatment.

Wojciech Jeżewski – President of Hemolens Diagnostics

Our values

Effectiveness

We push the boundaries of technology by delivering innovative solutions in the area of non-invasive diagnostics. We are target-driven.

Teamwork

For us, people come first. We share common goals and support one another in achieving them. We want no internal barriers. We engage and inspire our partners and each other.

Open-mindedness

We anticipate change and proactively manage it. We are flexible.

Through quality towards safety

We raise safety standards in patient diagnostics. Always growing, we strive for the utmost precision in diagnosing heart disease.

What do we do?

Building on expert medical knowledge and advanced technologies, we have created a new alternative diagnostic tool in cardiology – an innovative software that provides functional and quantitative information about coronary artery stenosis severit. We help physicians and health care institutions to get to the forefront of digital transformation in diagnostics, making the diagnostic process fast, accurate and safe.

Accurate diagnosis in patients with suspected ischemic heart disease thanks to a combination of two non-invasive diagnostic tools: coronary computed tomography angiography and continuous non-invasive blood pressure monitoring. This makes it possible to produce a 3D model of the blood vessels, allowing for a detailed anatomical and functional evaluation of coronary arteries and simultaneously delivering patient-specific hemodynamic results (FFR values) across all coronary arteries.

Our unmatched technology based on computational fluid dynamics and artificial intelligence provides physicians and their patients with access to a safe, non-invasive and highly accurate diagnostics for coronary artery disease.

HEMOLENS Technology

Patient benefits

  • Safe diagnostics
  • No stress or risk of complications
  • No need for hospital stay
  • No risk of nosocomial infection

Patient benefits

Physician benefits

  • Fewer invasive procedures for patients that do not need them
  • Optimum treatment planning and implementation
  • Reduces the need for invasive FFR measurements
  • Standardization of patient diagnosis
  • Convenience of a non-installable application

Physician benefits

Healthcare institution benefits

  • Better management of medical staff and invasive procedure planning
  • Reduced hospitalizations and related fixed and variable costs
  • One common diagnostic platform for cardiologists and radiologists
  • Use of state-of-the-art FFR measurement methods recommended by medical standards and scientific associations

Healthcare institution benefits

Founders of Hemolens Diagnostics

Kryspin Mirota

Co-founder, Scientist

Andrzej Kosior

Co-founder, Scientist

Wojciech Tarnawski

Co-founder, CTO

Hemolens Diagnostics Management Board

Wojciech Jeżewski

CEO

Wojciech Tarnawski

Co-founder, CTO

Tomasz Terlecki

CFO

Marcin Wierzbicki

COO

Supervisory Board

Tomasz Piec

Chairman and Member of the Supervisory Board

Mariusz Gromek

Member of the Supervisory Board

Marcin Stańczyk

Member of the Supervisory Board

Agnieszka Motyl

Member of the Supervisory Board

Our journey

2015

Establishment of the company.

2016

Proof of Concept presentation.

2017

Building the organization. Provisional patent application in the US.

2018

Beginning of medical trials. MVP readiness of a cloud-based solution. First positive results of clinical trials. Final patent applications in the US and EU.

2019

Continued clinicaltrials on 50 patients. CE-certification of the medical device iSIL-FFR.

2020

Establishing a five-year strategy. Increasing the engagement of investors. Establishment of an office in the Netherlands.

2021

Clinical research. Finalization of work on a new version of the medical device iSIL-FFR. Development of commercial competence.

Science Partners

National Institute of Cardiology of Stefan Cardinal Wyszyński - National Research Institute

Fourth Military Clinical Hospital with a Polyclinic, Independent Public Healthcare Center in Wrocław

Upper Silesian Medical Center Prof. Leszek Giec of the Medical University of Silesia in Katowice

Cracow Specialist Hospital JPII

University Clinical Hospital Jan Mikulicz-Radecki in Wrocław

T. Marciniak Special Hospital of Lower Silesia - Emergency Medicine Center in Wrocław

University Clinical Center at the Medical University of Gdańsk

Polish-American Heart Clinics, Cardiovascular Center

Polish-American Heart Clinics, Cardiovascular Center

University Hospital in Cracow

View current public procurement notices

We use cookies and similar technologies, incl. for the purposes of: providing services, advertising, statistics. Using the site without changing your browser settings means that they will be placed on your end device. Remember that you can always change these settings.